ConCallIQ
Go Pro
Home › Alkem Laboratories › Revenue History

Alkem Laboratories Revenue History — Quarter by Quarter

Alkem Laboratories's revenue moved from ₹3,371 Cr in Q1 FY26 to ₹3,737 Cr in Q3 FY26, a 10.9% change over 3 quarters. The table keeps each quarter linked back to the underlying earnings page.

Revenue by Quarter

QuarterRevenue (₹ Cr)YoY Change
Q3 FY26₹3,737 Cr+10.7%
Q2 FY26₹4,010 Cr+17.2%
Q1 FY26₹3,371 Cr+11.2%

What management said about revenue

G

Q3 FY26 · Domestic business to grow 100-150 bps above IPM

Management expects domestic business to continue growing 100-150 bps above IPM growth, with FY26 ending at ~10% growth.

G

Q3 FY26 · Occlutech revenue CAGR of 14% over 5 years

Occlutech is expected to grow at 14% CAGR over the next 5 years, reaching ~₹780 crore, excluding new products.

G

Q3 FY26 · Denosumab US entry by end of FY26

Denosumab US launch expected by end of FY26, pending FDA inspection and litigation resolution.

G

Q2 FY26 · India business to outperform IPM by 100-150 bps

Management expects India growth to continue at double-digit, outperforming the IPM by 100-150 bps in H2 and FY27.

G

Q2 FY26 · US CDMO plant to reach ₹300 cr annual revenue in 12-18 months

The US CDMO plant, operational from September, is expected to achieve an annual run-rate of ₹300 crore within 12-18 months.

G

Q2 FY26 · R&D spend to be 4-5% of revenue for FY26

R&D expenses were 3.3% in H1; management expects full-year R&D to be within 4-5% due to phasing of filings in Q4.

G

Q1 FY26 · R&D spend guidance of 4.5-5% of revenue for FY26

R&D expenses will be 4.5-5% of revenue for the full year, with higher spending in H2 due to filing cycles.

G

Q1 FY26 · Medtech business to break even by FY28

Medtech business expected to break even in FY28; FY26 and FY27 will see losses of ₹40-50 crore each.